These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38174435)

  • 21. Determination
    Thuku NW; Shikuku K; Mbugua A
    Pan Afr Med J; 2017; 27():226. PubMed ID: 28979628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products.
    Li J; de Korte D; Woolum MD; Ruane PH; Keil SD; Lockerbie O; McLean R; Goodrich RP
    Vox Sang; 2004 Aug; 87(2):82-90. PubMed ID: 15355498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of platelet function using the in vitro bleeding time and corrected count increment of transfused platelets. Comparison between platelet concentrates derived from pooled buffy coates and apheresis.
    Eriksson L; Kristensen J; Olsson K; Bring J; Högman CF
    Vox Sang; 1996; 70(2):69-75. PubMed ID: 8801766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Riboflavin and ultraviolet light treatment potentiates vasodilator-stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storage.
    Schubert P; Culibrk B; Coupland D; Scammell K; Gyongyossy-Issa M; Devine DV
    Transfusion; 2012 Feb; 52(2):397-408. PubMed ID: 21827504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative assessment of prophylactic transfusions of platelet concentrates obtained by the PRP or buffy-coat methods, in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Fernández-Muñoz H; Plaza EM; Rivera-Caravaca JM; Candela MJ; Romera M; De Arriba F; Lozano ML; Vicente V; Heras I; Castilla-Llorente C; Rivera J
    Hematology; 2018 Oct; 23(9):712-718. PubMed ID: 29582705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A system for the supply of platelets suspended in a storage medium including buffy-coat-derived platelet concentrates in combination with "split" apheresis platelets.
    Gulliksson H; Larsson S; Shanwell A; Pedajas I; Joie M; Flament J
    Transfus Sci; 1997 Mar; 18(1):33-40. PubMed ID: 10174289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality analysis of blood components obtained by automated buffy-coat layer removal with a top & bottom system (Optipress (R)II).
    Hurtado C; Bonanad S; Soler Mf; Mirabet V; Blasco I; Planelles Mf; De Miguel A
    Haematologica; 2000 Apr; 85(4):390-5. PubMed ID: 10756365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Donor platelet and leukocyte count as predictive factors of the quality of platelet concentrates obtained from whole blood by semiautomated fractionation.
    Cienfuegos-Pecina E; Leal-Nava ER; Avilés-Rodríguez LE; Llaca-Díaz JM; Pérez-Chávez F; Cázares-Tamez R; Díaz-Chuc EA
    Transfus Apher Sci; 2021 Feb; 60(1):102972. PubMed ID: 33127311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overcoming the bottleneck of platelet lysate supply in large-scale clinical expansion of adipose-derived stem cells: A comparison of fresh versus three types of platelet lysates from outdated buffy coat-derived platelet concentrates.
    Glovinski PV; Herly M; Mathiasen AB; Svalgaard JD; Borup R; Talman MM; Elberg JJ; Kølle ST; Drzewiecki KT; Fischer-Nielsen A
    Cytotherapy; 2017 Feb; 19(2):222-234. PubMed ID: 27887865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelet concentrates in an additive solution prepared from pooled buffy coats. In vivo studies.
    Eriksson L; Shanwell A; Gulliksson H; Högman CF; Svensson LA; Kristensen J; Berg B
    Vox Sang; 1993; 64(3):133-8. PubMed ID: 8484245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pooled platelet concentrates: an alternative to single donor apheresis platelets?
    Pietersz RN
    Transfus Apher Sci; 2009 Oct; 41(2):115-9. PubMed ID: 19716340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platelet storage lesion of WBC-reduced, pooled, buffy coat-derived platelet concentrates prepared in three in-process filter/storage bag combinations.
    Krailadsiri P; Seghatchian J; Williamson LM
    Transfusion; 2001 Feb; 41(2):243-50. PubMed ID: 11239230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microparticle and mitochondrial release during extended storage of different types of platelet concentrates.
    Marcoux G; Duchez AC; Rousseau M; Lévesque T; Boudreau LH; Thibault L; Boilard E
    Platelets; 2017 May; 28(3):272-280. PubMed ID: 27681879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of platelet concentrates prepared using different methods after overnight holding (18-24 h) of whole blood at room temperature.
    Mohanty D; Chaurasia R; Kumar A; Patidar GK; Pandey HC; Subramanian A
    Transfus Med; 2024 Aug; 34(4):311-318. PubMed ID: 38945170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stored platelet concentrates produced by the platelet-rich plasma method are more resistant to apoptosis but more sensitive to activation than are platelets prepared by the buffy-coat and apheresis methods.
    Leytin V; Allen DJ; Mutlu A; Mykhaylov S; Lyubimov E; Freedman J
    Transfusion; 2009 Jul; 49(7):1493-4. PubMed ID: 19602211
    [No Abstract]   [Full Text] [Related]  

  • 36. Overnight or fresh buffy coat-derived platelet concentrates prepared with various platelet pooling systems.
    Dijkstra-Tiekstra MJ; Kuipers W; Setroikromo AC; de Wildt-Eggen J
    Transfusion; 2008 Apr; 48(4):723-30. PubMed ID: 18208415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of platelet-derived extracellular vesicles in plateletpheresis concentrates: a multicenter study.
    Black A; Orsó E; Kelsch R; Pereira M; Kamhieh-Milz J; Salama A; Fischer MB; Meyer E; Frey BM; Schmitz G
    Transfusion; 2017 Jun; 57(6):1459-1469. PubMed ID: 28394090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Single-donor (apheresis) platelets and pooled whole-blood-derived platelets--significance and assessment of both blood products].
    Hitzler WE
    Clin Lab; 2014; 60(4):S1-39. PubMed ID: 24779310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality assessment of buffy-coat-derived leucodepleted platelet concentrates in PAS-plasma, prepared by the OrbiSac or TACSI automated system.
    Plaza EM; Céspedes P; Fernández H; Sánchez-Guiu MI; Egea JM; Vicente V; Lozano ML; Rivera J
    Vox Sang; 2014 Jan; 106(1):38-44. PubMed ID: 23888911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Are Buffy-coat Pooled Platelet Concentrates an Effective Alternative to Apheresis Platelet Concentrates? An
    Agarwal P; Jain A; Elhence P; Verma A
    Int J Appl Basic Med Res; 2023; 13(3):175-179. PubMed ID: 38023597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.